We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Birds in bush

3 November 2020 By Robert Cyran

The pharma firm had to sell assets to close its $74 bln purchase of Celgene in 2019. It took a high-risk gamble – sell a blockbuster to Amgen and keep an unproven drug. A trial shows it got the better end of the bargain. Bristol increasingly looks like it bought Celgene cheap.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)